Pneumonia News and Research

Latest Pneumonia News and Research

Innovaro facilitates protein transduction technology licensing between Trojan Technologies, Trojantec

Innovaro, a comprehensive innovation solutions company, is pleased to announce that it has facilitated the completion of a licensing transaction between Trojan Technologies USA, a company recently formed by Verdant Ventures Advisors II, LLC, and Trojantec Ltd, a London and Cyprus based biopharmaceutical company.

11 Jun 2010

Extensive usage of antibiotic linezolid associated with ICU outbreak of LRSA

An outbreak of infection due to linezolid and methicillin-resistant Staphylococcus aureus (LRSA) in 12 intensive care unit patients in Spain was associated with transmission within the hospital and extensive usage of the antibiotic linezolid, often used for the treatment of serious infections, with reductions in linezolid use and infection-control measures associated with resolution of the outbreak, according to a study in the June 9 issue of JAMA.

10 Jun 2010

Caregiver's guide on avoiding life-threatening swallowing problems

That's the message of Drs. Roya Sayadi and Joel Herskowitz. They are a wife-husband team from Natick, Massachusetts, who are spreading the word that swallowing problems are everywhere - and they can be deadly!

10 Jun 2010

Study reveals insurance related differences in hospital mortality for AMI, stroke, pneumonia

An analysis of over 150,000 hospital discharges has revealed that there are significant insurance related differences in hospital mortality, length of stay, and costs among working-age Americans (age 18-64 years) hospitalized for acute myocardial infarction (AMI), stroke, or pneumonia. These three conditions are among the leading causes of non-cancer in-patient deaths in patients under 65 years old. The analysis is published today in the Journal of Hospital Medicine.

10 Jun 2010

Overall death rate for patients developed complications during hospitalization fell by 23%: AHRQ

Fewer hospital patients died from complications in their health care between 2001 and 2006, but Asians/Pacific Islanders and Hispanics were less likely to survive than either whites or blacks, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

10 Jun 2010

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).

9 Jun 2010

Clinical guidelines for UC emergency medicine physicians

Though guidelines for best treatment practices are common, they are only partially effective without standardized, routine exposure to them in clinical practice, according to a study conducted by University of Cincinnati emergency medicine researchers.

9 Jun 2010

U.S. Court issues claim construction order in patent infringement litigation between Cubist and Teva

Cubist Pharmaceuticals, Inc. today announced that the U.S. District Court for the District of Delaware issued a claim construction order in the litigation between Cubist and Teva.

8 Jun 2010

Lack of community focus and poor coordination hamper UN initiative for maternal, child Health

A new United Nations initiative designed to improve global maternal, newborn and child health is a welcome development but neglects to address some important action points, according to World Vision, the world's largest international humanitarian organization focusing on the well-being of children.

8 Jun 2010

Rice University students develop new device to help children with acute respiratory infections

Gently, gently. That's how babies should be handled, and it was the prime consideration when a team of Rice University seniors developed a device that could save babies' lives.

8 Jun 2010

Gates Foundation to invest $1.5 billion for integrated women's and children's health programs

Melinda Gates today urged global leaders to make women's and children's health a top priority, and announced that the Gates Foundation will invest $1.5 billion over the next five years to support maternal and child health, family planning, and nutrition programs in developing countries.

8 Jun 2010

BGS develops new bio filters for testing E. coli, salmonella, listeria and pseudomonas in food samples

BioSpec Global Solutions Inc., and partner -ICBS Ltd., announced today that it has begun development of three new bio filter for the testing of E. coli, salmonella, listeria and pseudomonas in food samples. Development of the Antibody/antigen multiple discrete filters and optical system for the simultaneous analysis of E.coli, salmonella, listeria and pseudomonas in food samples.

7 Jun 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.

7 Jun 2010

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Onyx Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 2 study, known as the 004 study. Carfilzomib, a selective, next-generation proteasome inhibitor, demonstrated encouraging overall response rates (ORR), tolerability and durable disease control when administered as a single-agent in patients with relapsed and/or refractory multiple myeloma.

7 Jun 2010

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Millennium: The Takeda Oncology Company today announced data examining the use of VELCADE in the treatment of patients with relapsed or refractory light chain (AL) amyloidosis. Amyloidosis is a rare condition in which excessive proteins build up in organs or tissues, such as the heart, kidney or liver. These data were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois, June 4-8, 2010.

5 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Pneumonia News and Research

Latest Pneumonia News and Research

Innovaro facilitates protein transduction technology licensing between Trojan Technologies, Trojantec

Extensive usage of antibiotic linezolid associated with ICU outbreak of LRSA

Caregiver's guide on avoiding life-threatening swallowing problems

Study reveals insurance related differences in hospital mortality for AMI, stroke, pneumonia

Overall death rate for patients developed complications during hospitalization fell by 23%: AHRQ

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Clinical guidelines for UC emergency medicine physicians

U.S. Court issues claim construction order in patent infringement litigation between Cubist and Teva

Lack of community focus and poor coordination hamper UN initiative for maternal, child Health

Rice University students develop new device to help children with acute respiratory infections

Gates Foundation to invest $1.5 billion for integrated women's and children's health programs

BGS develops new bio filters for testing E. coli, salmonella, listeria and pseudomonas in food samples

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

McMaster University researchers discover chemical clue directing Staphylococcus aureus

Legionnaires' disease kills a 66 year old

Tetraphase Pharmaceuticals raises $45M in Series C financing

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Pneumonia News and Research

Latest Pneumonia News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in